Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, ...

GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) ...

A new mRNA and lipid nanoparticle (mRNA-LNP) platform could selectively reprogram in vivo cytotoxic effector T cells (Teff), ...

I’ve covered the ageing field for many years and seen a lot of promising rejuvenation therapies get hyped up then fall flat on their faces. Ground zero for this repeated cycle was resveratrol, a ...

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...

As blood stem cells age, their lysosomes become overactive and damaged, triggering inflammation and weakening the body’s ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

In certain contexts, the Notch receptor may participate in “reverse signaling,” influencing neighboring cells directly.

CTA313 achieved an SRI-4 response, with half achieving remissionBOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic ...